HAE - Haemonetics Corp Stock Price, Fair Value and News

93.31USD-1.89 (-1.99%)Market Closed

Market Summary

USD93.31-1.89

Market Closed

-1.99%

HAE Stock Price

View Fullscreen

HAE RSI Chart

HAE Valuation

Market Cap

4.7B

Price/Earnings (Trailing)

37.44

Price/Sales (Trailing)

3.73

EV/EBITDA

21.22

Price/Free Cashflow

36.81

HAE Price/Sales (Trailing)

HAE Profitability

EBT Margin

12.68%

Return on Equity

13.42%

Return on Assets

5.75%

Free Cashflow Yield

2.72%

HAE Fundamentals

HAE Revenue

Revenue (TTM)

1.3B

Rev. Growth (Yr)

10.14%

Rev. Growth (Qtr)

5.68%

HAE Earnings

Earnings (TTM)

126.6M

Earnings Growth (Yr)

-5.17%

Earnings Growth (Qtr)

25.43%

Breaking Down HAE Revenue

Last 7 days

1.3%

Last 30 days

9.4%

Last 90 days

19.5%

Trailing 12 Months

14.6%

How does HAE drawdown profile look like?

HAE Financial Health

Current Ratio

2.92

Debt/Equity

0.91

Debt/Cashflow

0.23

HAE Investor Care

Shares Dilution (1Y)

0.67%

Diluted EPS (TTM)

2.47

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.2B	1.2B	1.2B	1.3B
2022	993.2M	1.0B	1.1B	1.1B
2021	870.5M	903.4M	933.8M	953.2M
2020	988.5M	945.6M	902.5M	883.9M
2019	967.6M	976.7M	987.7M	999.3M
2018	903.9M	922.3M	938.5M	951.8M
2017	886.1M	887.1M	892.2M	898.4M
2016	908.8M	905.4M	905.9M	900.4M
2015	910.4M	899.3M	891.4M	893.0M
2014	938.5M	943.5M	935.3M	925.0M
2013	892.0M	935.1M	952.6M	947.4M
2012	727.8M	733.8M	772.5M	828.7M
2011	676.7M	684.2M	696.8M	711.2M
2010	645.4M	654.4M	664.1M	675.8M
2009	597.9M	609.8M	621.7M	633.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Haemonetics Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 06, 2024	lingamneni anila	sold	-218,975	95.00	-2,305	evp, chief technology officer
May 02, 2024	darecca james	sold (taxes)	-40,318	93.33	-432	evp, chief financial officer
Apr 15, 2024	lingamneni anila	sold (taxes)	-15,617	84.88	-184	evp, chief technology officer
Mar 11, 2024	simon, christopher	gifted	-	-	-38,900	president & ceo
Nov 01, 2023	galvin roy	sold (taxes)	-13,822	86.39	-160	president, global plasma & bc
Oct 20, 2023	basil michelle l	sold (taxes)	-17,542	89.05	-197	evp and general counsel
Oct 20, 2023	strong stewart w	sold (taxes)	-10,686	89.05	-120	president, global hospital
Sep 15, 2023	miller laurie a.	sold (taxes)	-18,833	90.11	-209	svp, human resources
Sep 12, 2023	strong stewart w	sold	-20,668	90.65	-228	president, global hospital
Sep 11, 2023	lingamneni anila	sold	-207,450	90.00	-2,305	evp, chief technology officer

Which funds bought or sold HAE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	QRG CAPITAL MANAGEMENT, INC.	reduced	-10.19	-37,201	321,855	-%
May 07, 2024	PANAGORA ASSET MANAGEMENT INC	reduced	-14.79	-533,804	3,037,520	0.02%
May 07, 2024	Inspire Investing, LLC	reduced	-5.79	-22,822	360,006	0.04%
May 07, 2024	NEW YORK STATE COMMON RETIREMENT FUND	added	38.64	1,829,000	6,081,000	0.01%
May 07, 2024	SEI INVESTMENTS CO	unchanged	-	9,414	307,564	-%
May 07, 2024	HEARTLAND ADVISORS INC	reduced	-1.19	-1,307,610	18,697,200	0.98%
May 07, 2024	Swiss National Bank	unchanged	-	-15,984	8,526,460	0.01%
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	reduced	-62.39	-2,088,450	1,254,990	-%
May 07, 2024	Washington Trust Advisors, Inc.	unchanged	-	-17.00	8,706	-%
May 07, 2024	Headlands Technologies LLC	new	-	114,198	114,198	0.03%

Are Funds Buying or Selling HAE?

Are funds buying HAE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own HAE

No. of Funds

Unveiling Haemonetics Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	neuberger berman group llc	6.96%	3,531,181	SC 13G/A
Feb 13, 2024	vanguard group inc	10.65%	5,406,309	SC 13G/A
Feb 09, 2024	capital research global investors	12.9%	6,523,568	SC 13G/A
Feb 08, 2024	wellington management group llp	6.44%	3,268,083	SC 13G/A
Jan 23, 2024	blackrock inc.	11.9%	6,056,881	SC 13G/A
Feb 13, 2023	capital research global investors	11.8%	5,956,064	SC 13G/A
Feb 10, 2023	neuberger berman group llc	7.65%	3,873,436	SC 13G/A
Feb 09, 2023	vanguard group inc	10.36%	5,242,836	SC 13G/A
Feb 06, 2023	wellington management group llp	7.97%	4,034,753	SC 13G/A
Jan 26, 2023	blackrock inc.	11.7%	5,898,620	SC 13G/A

Recent SEC filings of Haemonetics Corp

View All Filings

Date Filed	Form Type	Document
May 08, 2024	4	Insider Trading
May 06, 2024	4	Insider Trading
May 06, 2024	144	Notice of Insider Sale Intent
May 01, 2024	8-K	Current Report
Apr 17, 2024	4	Insider Trading
Apr 01, 2024	8-K	Current Report
Mar 13, 2024	4	Insider Trading
Mar 05, 2024	8-K	Current Report
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Haemonetics Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	182.6B	40.3B	-5.05%	-4.82%	32.45	4.53	-2.84%	-3.08%
BDX	67.4B	19.7B	-3.45%	-6.52%	50.6	3.42	4.82%	-17.56%
ALGN	20.6B	3.9B	-14.54%	-9.65%	44.54	5.26	5.72%	46.72%
BAX	18.2B	14.9B	-15.38%	-17.01%	6.88	1.22	2.98%	207.68%
MID-CAP
ATR	10.0B	3.5B	7.32%	25.05%	31.94	2.82	6.16%	35.06%
HSIC	9.3B	12.5B	0.39%	-2.78%	24.01	0.75	-0.61%	-18.83%
BIO	7.6B	2.6B	-17.82%	-26.90%	-23.72	2.94	-6.25%	-68.62%
XRAY	5.8B	3.9B	-13.74%	-32.04%	-61.76	1.47	0.23%	91.03%
AXNX	3.4B	387.1M	-0.59%	20.47%	-215.56	8.87	30.82%	65.57%
PDCO	2.3B	6.6B	-1.26%	-0.69%	11.98	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.92%	-14.34%	-1.85	0.4	7.94%	-1661.78%
ANIK	423.5M	169.3M	11.74%	12.93%	-5.51	2.5	7.49%	-244.90%
ANGO	236.7M	324.0M	-10.59%	-34.33%	-1.23	0.73	-3.19%	-337.41%
APYX	45.4M	52.3M	-10.27%	-60.90%	-2.43	0.87	17.61%	19.28%
AEMD	3.3M	3.7M	-25.00%	250.00%	-0.27	0.88	5.77%	8.23%

Haemonetics Corp News

Latest updates

Haemonetics Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	5.7%	336	318	311	304	305	297	261	265	260	240	229	225	240	209	196	238	259	253	238	249	247
Gross Profit	4.3%	178	171	167	156	159	158	142	136	139	123	108	82.00	120	106	90.00	114	128	127	116	111	111
Operating Expenses	-2.5%	132	135	114	121	115	111	111	117	103	98.00	107	103	80.00	47.00	78.00	88.00	87.00	77.00	129	87.00	83.00
S&GA Expenses	6.5%	112	105	93.00	98.00	95.00	92.00	92.00	92.00	81.00	76.00	91.00	84.00	66.00	64.00	62.00	53.00	78.00	78.00	73.00	54.00	74.00
R&D Expenses	4.7%	13.00	13.00	13.00	16.00	13.00	11.00	11.00	13.00	10.00	11.00	13.00	11.00	8.00	7.00	8.00	9.00	7.00	7.00	7.00	9.00	9.00
EBITDA Margin	-1.8%	0.20*	0.20*	0.23*	0.21*	0.20*	0.20*	0.19*	0.17*	0.13*	0.13*	0.17*	0.19*	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	1.00	2.00	1.00	2.00	3.00	2.00	4.00	3.00	4.00	4.00	4.00
Income Taxes	61.4%	13.00	8.00	11.00	3.00	9.00	8.00	6.00	6.00	8.00	5.00	1.00	-16.38	6.00	7.00	-2.50	4.00	8.00	8.00	-9.25	1.00	7.00
Earnings Before Taxes	34.1%	44.00	33.00	52.00	33.00	42.00	41.00	25.00	15.00	31.00	20.00	-3.01	-27.40	37.00	55.00	8.00	22.00	38.00	45.00	-17.73	22.00	25.00
EBT Margin	-1.3%	0.13*	0.13*	0.14*	0.12*	0.11*	0.10*	0.09*	0.06*	0.02*	0.03*	0.07*	0.08*	-	-	-	-	-	-	-	-	-
Net Income	25.4%	31.00	25.00	41.00	29.00	33.00	33.00	20.00	10.00	23.00	15.00	-4.45	-11.04	32.00	48.00	11.00	18.00	30.00	37.00	-8.48	21.00	-8.48
Net Income Margin	-3.7%	0.10*	0.10*	0.11*	0.10*	0.08*	0.08*	0.07*	0.04*	0.02*	0.03*	0.07*	0.09*	-	-	-	-	-	-	-	-	-
Free Cashflow	-130.7%	-22.83	74.00	9.00	68.00	48.00	51.00	-3.47	33.00	36.00	23.00	-15.60	-10.09	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	9.4%	2,200	2,011	1,962	1,935	1,878	1,865	1,821	1,860	1,831	1,801	1,794	1,820	1,318	1,418	1,433	1,267	1,238	1,191	1,260	1,275	1,228
Current Assets	-11.6%	765	866	802	770	706	716	688	756	729	699	684	694	668	760	759	604	583	568	615	576	516
Cash Equivalents	-44.7%	194	351	286	284	224	241	215	259	237	192	173	192	189	279	276	137	126	112	190	169	155
Inventory	6.4%	304	286	289	259	256	255	278	293	306	323	327	323	300	305	295	270	254	245	222	194	169
Net PPE	3.5%	319	308	304	311	313	308	288	258	239	224	215	218	240	240	243	253	268	264	277	344	351
Goodwill	19.3%	555	465	466	466	466	465	466	467	468	469	466	466	216	215	217	8.00	211	211	211	211	211
Current Liabilities	-0.9%	262	264	237	252	227	262	180	442	355	288	228	253	194	339	408	275	257	240	294	236	211
Long Term Debt	14.5%	857	749	751	754	757	760	763	559	633	698	767	691	293	297	297	306	310	314	318	322	327
LT Debt, Current	1.3%	14.00	14.00	14.00	12.00	10.00	58.00	7.00	214	144	83.00	17.00	17.00	17.00	167	231	77.00	62.00	57.00	118	28.00	17.00
LT Debt, Non Current	14.5%	857	749	751	754	757	760	763	559	633	698	767	691	293	297	297	306	310	314	318	322	327
Shareholder's Equity	5.6%	943	894	865	818	776	729	770	749	731	699	677	732	719	668	609	587	575	584	591	668	591
Retained Earnings	10.1%	340	309	284	253	224	204	222	202	193	169	155	158	169	137	89.00	79.00	70.00	86.00	99.00	161	141
Additional Paid-In Capital	1.6%	627	617	610	595	587	564	580	572	567	558	551	603	579	569	563	553	538	534	525	536	531
Shares Outstanding	0.1%	51.00	51.00	51.00	50.00	51.00	51.00	51.00	51.00	51.00	51.00	51.00	51.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	3,725	-	-	-	3,658	-	-	-	4,380	-	-	-	6,235	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-100.5%	-540	99,124	19,086	79,611	64,415	87,039	41,993	68,050	62,433	43,460	-1,680	1,547	66,291	29,155	11,812	46,406	79,282	29,901	2,628	20,638	58,164
Share Based Compensation	7.6%	7,217	6,706	6,989	7,058	7,491	5,735	5,299	5,097	6,455	5,979	6,828	7,110	6,287	5,952	6,167	5,399	5,325	5,000	4,730	4,445	4,782
Cashflow From Investing	-970.0%	-268,937	-25,135	-15,261	-18,006	-36,500	-31,068	-58,214	-34,512	-15,462	-20,520	-15,851	-429,100	-9,581	37,135	-23,896	-45,135	-19,866	5,964	1,861	-13,217	-27,585
Cashflow From Financing	1625.8%	109,429	-7,172	-598	-1,603	-49,680	-25,686	-23,395	-8,765	-2,035	-3,315	-1,634	432,759	-149,940	-64,318	148,951	11,372	-46,153	-112,517	16,090	6,995	-76,207
Buy Backs	-	-	-	-	-	-	75,000	-	-	-	-	-	-	-	-	-	-	50,000	50,000	75,000	2,500	75,000

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

HAE Income Statement

2023-12-30

CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 30, 2023	Dec. 31, 2022	Dec. 30, 2023	Dec. 31, 2022
Income Statement [Abstract]
Net revenues	$ 336,250	$ 305,301	$ 965,765	$ 864,244
Cost of goods sold	158,383	146,594	450,123	405,396
Gross profit	177,867	158,707	515,642	458,848
Operating expenses:
Research and development	13,265	12,689	38,578	34,487
Selling, general and administrative	111,713	94,661	310,099	278,917
Amortization of acquired intangible assets	6,911	8,078	21,606	24,666
Impairment of assets	0	0	10,419	0
Total operating expenses	131,889	115,428	380,702	338,070
Operating income	45,978	43,279	134,940	120,778
Interest and other expense, net	(1,949)	(1,055)	(6,489)	(12,001)
Income before provision for income taxes	44,029	42,224	128,451	108,777
Provision for income taxes	12,788	9,280	31,260	22,759
Net income	$ 31,241	$ 32,944	$ 97,191	$ 86,018
Basic income (loss) per share (in dollars per share)	$ 0.62	$ 0.65	$ 1.92	$ 1.69
Diluted income (loss) per share (in dollars per share)	$ 0.61	$ 0.64	$ 1.89	$ 1.67
Weighted average shares outstanding
Basic (in shares)	50,768	50,509	50,679	50,896
Diluted (in shares)	51,445	51,219	51,394	51,487
Comprehensive income	$ 39,564	$ 37,400	$ 103,190	$ 76,173

HAE Balance Sheet

2023-12-30

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 30, 2023	Apr. 01, 2023
Current assets:
Cash and cash equivalents	$ 193,978	$ 284,466
Accounts receivable, less allowance for credit losses of $5,725 at December 30, 2023 and $4,932 at April 1, 2023	211,611	179,142
Inventories, net	304,024	259,379
Prepaid expenses and other current assets	55,369	46,735
Total current assets	764,982	769,722
Property, plant and equipment, net	318,665	310,885
Intangible assets, less accumulated amortization of $442,810 at December 30, 2023 and $417,422 at April 1, 2023	429,270	275,771
Goodwill	554,999	466,231
Deferred tax asset	5,070	5,241
Other long-term assets	127,442	106,975
Total assets	2,200,428	1,934,825
Current liabilities:
Notes payable and current maturities of long-term debt	13,736	11,784
Accounts payable	56,845	63,929
Accrued payroll and related costs	58,762	64,475
Other current liabilities	132,412	111,628
Total current liabilities	261,755	251,816
Long-term debt	856,849	754,102
Deferred tax liability	62,246	36,195
Other long-term liabilities	76,259	74,715
Stockholders’ equity:
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 50,785,040 shares at December 30, 2023 and 50,448,519 shares at April 1, 2023	508	504
Additional paid-in capital	627,094	594,706
Retained earnings	340,099	253,168
Accumulated other comprehensive loss	(24,382)	(30,381)
Stockholders’ equity:	943,319	817,997
Total liabilities and stockholders’ equity	$ 2,200,428	$ 1,934,825

About Haemonetics Corp

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

CEO	Mr. Christopher A. Simon
WEBSITE	haemonetics.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	3034

Haemonetics Corp Frequently Asked Questions

What is the ticker symbol for Haemonetics Corp? What does HAE stand for in stocks?

HAE is the stock ticker symbol of Haemonetics Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Haemonetics Corp (HAE)?

As of Wed May 08 2024, market cap of Haemonetics Corp is 4.74 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HAE stock?

You can check HAE's fair value in chart for subscribers.

What is the fair value of HAE stock?

You can check HAE's fair value in chart for subscribers. The fair value of Haemonetics Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Haemonetics Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HAE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Haemonetics Corp a good stock to buy?

The fair value guage provides a quick view whether HAE is over valued or under valued. Whether Haemonetics Corp is cheap or expensive depends on the assumptions which impact Haemonetics Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HAE.

What is Haemonetics Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, HAE's PE ratio (Price to Earnings) is 37.44 and Price to Sales (PS) ratio is 3.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HAE PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Haemonetics Corp's stock?

In the past 10 years, Haemonetics Corp has provided 0.111 (multiply by 100 for percentage) rate of return.